Annual CFF
$218.46 M
+$214.38 M+5259.62%
31 December 2023
Summary:
Celldex Therapeutics annual cash flow from financing activities is currently $218.46 million, with the most recent change of +$214.38 million (+5259.62%) on 31 December 2023. During the last 3 years, it has risen by +$47.23 million (+27.58%). CLDX annual CFF is now -24.57% below its all-time high of $289.60 million, reached on 31 December 2013.CLDX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.24 M
-$2.47 M-66.62%
01 September 2024
Summary:
Celldex Therapeutics quarterly cash flow from financing activities is currently $1.24 million, with the most recent change of -$2.47 million (-66.62%) on 01 September 2024. Over the past year, it has increased by +$982.00 thousand (+382.10%). CLDX quarterly CFF is now -99.72% below its all-time high of $436.11 million, reached on 31 March 2024.CLDX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$658.44 M
+$982.00 K+0.15%
01 September 2024
Summary:
Celldex Therapeutics TTM cash flow from financing activities is currently $658.44 million, with the most recent change of +$982.00 thousand (+0.15%) on 01 September 2024. Over the past year, it has increased by +$655.96 million (+26460.59%). CLDX TTM CFF is now at all-time high.CLDX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5259.6% | +382.1% | +10000.0% |
| 3 y3 years | +27.6% | -99.5% | +142.1% |
| 5 y5 years | +642.0% | -49.7% | +3683.3% |
CLDX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -19.8% | +5259.6% | -99.7% | +1645.1% | at high | >+9999.0% |
| 5 y | 5 years | -19.8% | +5259.6% | -99.7% | +5056.0% | at high | >+9999.0% |
| alltime | all time | -24.6% | +8962.4% | -99.7% | +113.6% | at high | >+9999.0% |
Celldex Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.24 M(-66.6%) | $658.44 M(+0.1%) |
| June 2024 | - | $3.71 M(-99.1%) | $657.46 M(+0.5%) |
| Mar 2024 | - | $436.11 M(+100.6%) | $653.88 M(+199.3%) |
| Dec 2023 | $218.46 M(+5259.6%) | $217.37 M(>+9900.0%) | $218.46 M(+8712.3%) |
| Sept 2023 | - | $257.00 K(+93.2%) | $2.48 M(-45.3%) |
| June 2023 | - | $133.00 K(-80.8%) | $4.53 M(+1.4%) |
| Mar 2023 | - | $694.00 K(-50.3%) | $4.47 M(+9.6%) |
| Dec 2022 | $4.08 M(-98.5%) | $1.40 M(-39.5%) | $4.08 M(+31.2%) |
| Sept 2022 | - | $2.31 M(+3147.9%) | $3.11 M(-98.9%) |
| June 2022 | - | $71.00 K(-76.6%) | $272.70 M(+0.0%) |
| Mar 2022 | - | $304.00 K(-28.6%) | $272.60 M(+0.1%) |
| Dec 2021 | $272.37 M(+59.1%) | $426.00 K(-99.8%) | $272.37 M(+0.1%) |
| Sept 2021 | - | $271.90 M(<-9900.0%) | $271.99 M(+5833.5%) |
| June 2021 | - | -$25.00 K(-133.8%) | $4.58 M(-97.3%) |
| Mar 2021 | - | $74.00 K(+68.2%) | $169.66 M(-0.9%) |
| Dec 2020 | $171.23 M(+953.2%) | $44.00 K(-99.0%) | $171.23 M(-1.4%) |
| Sept 2020 | - | $4.49 M(-97.3%) | $173.60 M(+1.2%) |
| June 2020 | - | $165.05 M(>+9900.0%) | $171.58 M(+1149.3%) |
| Mar 2020 | - | $1.64 M(-32.4%) | $13.73 M(-15.5%) |
| Dec 2019 | $16.26 M(-44.8%) | $2.42 M(-1.7%) | $16.26 M(-6.6%) |
| Sept 2019 | - | $2.46 M(-65.8%) | $17.40 M(-15.0%) |
| June 2019 | - | $7.21 M(+73.4%) | $20.48 M(-4.9%) |
| Mar 2019 | - | $4.16 M(+16.6%) | $21.54 M(-26.8%) |
| Dec 2018 | $29.44 M(-42.6%) | $3.57 M(-35.6%) | $29.44 M(-33.6%) |
| Sept 2018 | - | $5.54 M(-33.0%) | $44.33 M(-11.4%) |
| June 2018 | - | $8.27 M(-31.4%) | $50.06 M(-0.8%) |
| Mar 2018 | - | $12.06 M(-34.6%) | $50.46 M(-1.6%) |
| Dec 2017 | $51.29 M(+254.2%) | $18.46 M(+63.8%) | $51.29 M(+42.0%) |
| Sept 2017 | - | $11.27 M(+30.0%) | $36.12 M(+9.0%) |
| June 2017 | - | $8.67 M(-32.8%) | $33.15 M(+22.3%) |
| Mar 2017 | - | $12.90 M(+292.7%) | $27.10 M(+87.1%) |
| Dec 2016 | $14.48 M(-92.5%) | $3.28 M(-60.4%) | $14.48 M(+25.8%) |
| Sept 2016 | - | $8.30 M(+216.7%) | $11.52 M(+191.2%) |
| June 2016 | - | $2.62 M(+835.7%) | $3.95 M(+136.5%) |
| Mar 2016 | - | $280.00 K(-11.9%) | $1.67 M(-99.1%) |
| Dec 2015 | $193.15 M(>+9900.0%) | $318.00 K(-56.8%) | $193.15 M(+0.2%) |
| Sept 2015 | - | $736.00 K(+117.8%) | $192.84 M(+0.2%) |
| June 2015 | - | $338.00 K(-99.8%) | $192.41 M(+0.1%) |
| Mar 2015 | - | $191.76 M(>+9900.0%) | $192.23 M(>+9900.0%) |
| Dec 2014 | $1.17 M(-99.6%) | $11.00 K(-96.4%) | $1.17 M(-99.4%) |
| Sept 2014 | - | $304.00 K(+97.4%) | $184.71 M(-0.2%) |
| June 2014 | - | $154.00 K(-78.1%) | $185.03 M(+5.3%) |
| Mar 2014 | - | $702.00 K(-99.6%) | $175.79 M(-39.3%) |
| Dec 2013 | $289.60 M(+263.1%) | $183.55 M(>+9900.0%) | $289.60 M(+130.5%) |
| Sept 2013 | - | $622.00 K(-106.8%) | $125.62 M(-6.7%) |
| June 2013 | - | -$9.09 M(-107.9%) | $134.58 M(-5.5%) |
| Mar 2013 | - | $114.51 M(+485.0%) | $142.35 M(+78.5%) |
| Dec 2012 | $79.76 M(+180.5%) | $19.57 M(+104.3%) | $79.76 M(+32.2%) |
| Sept 2012 | - | $9.58 M(-831.9%) | $60.31 M(+18.9%) |
| June 2012 | - | -$1.31 M(-102.5%) | $50.71 M(-42.3%) |
| Mar 2012 | - | $51.91 M(>+9900.0%) | $87.90 M(+209.1%) |
| Dec 2011 | $28.43 M(+162.9%) | $129.00 K(-660.9%) | $28.43 M(-25.7%) |
| Sept 2011 | - | -$23.00 K(-100.1%) | $38.27 M(-0.9%) |
| June 2011 | - | $35.88 M(-575.3%) | $38.62 M(+1135.1%) |
| Mar 2011 | - | -$7.55 M(-175.8%) | $3.13 M(-71.1%) |
| Dec 2010 | $10.82 M(-538.8%) | $9.96 M(+2882.3%) | $10.82 M(-650.2%) |
| Sept 2010 | - | $334.00 K(-12.3%) | -$1.97 M(-15.7%) |
| June 2010 | - | $381.00 K(+170.2%) | -$2.33 M(+2.1%) |
| Mar 2010 | - | $141.00 K(-105.0%) | -$2.28 M(-7.4%) |
| Dec 2009 | -$2.46 M(-122.6%) | -$2.82 M(+9003.2%) | -$2.46 M(-730.8%) |
| Sept 2009 | - | -$31.00 K(-107.2%) | $390.80 K(+17.4%) |
| June 2009 | - | $429.00 K(-1146.3%) | $332.80 K(-96.9%) |
| Mar 2009 | - | -$41.00 K(-221.3%) | $10.76 M(-1.6%) |
| Dec 2008 | $10.93 M(+4033.6%) | $33.80 K(-138.0%) | $10.93 M(-0.5%) |
| Sept 2008 | - | -$89.00 K(-100.8%) | $10.98 M(-3.4%) |
| June 2008 | - | $10.85 M(+8318.5%) | $11.37 M(+3435.4%) |
| Mar 2008 | - | $128.90 K(+41.8%) | $321.70 K(+21.7%) |
| Dec 2007 | $264.30 K | $90.90 K(-69.9%) | $264.30 K(-89.0%) |
| Sept 2007 | - | $302.20 K(-250.9%) | $2.41 M(+16.9%) |
| June 2007 | - | -$200.30 K(-380.1%) | $2.06 M(-6.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | $71.50 K(-96.8%) | $2.21 M(+6.6%) |
| Dec 2006 | $2.08 M(-1677.5%) | $2.24 M(-4894.9%) | $2.08 M(-1184.9%) |
| Sept 2006 | - | -$46.70 K(-5.5%) | -$191.50 K(+4.5%) |
| June 2006 | - | -$49.40 K(-24.7%) | -$183.30 K(+8.6%) |
| Mar 2006 | - | -$65.60 K(+120.1%) | -$168.80 K(+28.2%) |
| Dec 2005 | -$131.70 K(-100.5%) | -$29.80 K(-22.6%) | -$131.70 K(-106.5%) |
| Sept 2005 | - | -$38.50 K(+10.3%) | $2.04 M(-3.5%) |
| June 2005 | - | -$34.90 K(+22.5%) | $2.11 M(-2.1%) |
| Mar 2005 | - | -$28.50 K(-101.3%) | $2.16 M(-91.5%) |
| Dec 2004 | $25.50 M(+179.3%) | $2.14 M(+5788.4%) | $25.50 M(+9.5%) |
| Sept 2004 | - | $36.30 K(+249.0%) | $23.29 M(-28.4%) |
| June 2004 | - | $10.40 K(-100.0%) | $32.54 M(+0.0%) |
| Mar 2004 | - | $23.31 M(<-9900.0%) | $32.52 M(+256.2%) |
| Dec 2003 | $9.13 M(-9690.1%) | -$64.40 K(-100.7%) | $9.13 M(+0.3%) |
| Sept 2003 | - | $9.28 M(<-9900.0%) | $9.10 M(-4270.9%) |
| June 2003 | - | -$5400.00(-93.5%) | -$218.20 K(+2.5%) |
| Mar 2003 | - | -$82.50 K(-11.6%) | -$212.80 K(+123.5%) |
| Dec 2002 | -$95.20 K(-100.7%) | -$93.30 K(+152.2%) | -$95.20 K(-100.7%) |
| Sept 2002 | - | -$37.00 K(<-9900.0%) | $13.58 M(-0.7%) |
| June 2002 | - | $0.00(-100.0%) | $13.68 M(-1.2%) |
| Mar 2002 | - | $35.10 K(-99.7%) | $13.84 M(-1.8%) |
| Dec 2001 | $14.09 M(-66.4%) | $13.58 M(>+9900.0%) | $14.09 M(+327.9%) |
| Sept 2001 | - | $58.40 K(-63.3%) | $3.29 M(-91.4%) |
| June 2001 | - | $159.30 K(-44.6%) | $38.32 M(-0.2%) |
| Mar 2001 | - | $287.80 K(-89.7%) | $38.40 M(-8.5%) |
| Dec 2000 | $41.96 M(+321.6%) | $2.79 M(-92.1%) | $41.96 M(+7.0%) |
| Sept 2000 | - | $35.08 M(>+9900.0%) | $39.22 M(+179.4%) |
| June 2000 | - | $237.40 K(-93.8%) | $14.04 M(+1.7%) |
| Mar 2000 | - | $3.85 M(+7228.4%) | $13.80 M(+38.7%) |
| Dec 1999 | $9.95 M(+169.0%) | $52.50 K(-99.5%) | $9.95 M(+0.5%) |
| Sept 1999 | - | $9.90 M(>+9900.0%) | $9.90 M(>+9900.0%) |
| June 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1999 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 1998 | $3.70 M(>+9900.0%) | $0.00(0.0%) | $3.70 M(0.0%) |
| Sept 1998 | - | $0.00(0.0%) | $3.70 M(0.0%) |
| June 1998 | - | $0.00(-100.0%) | $3.70 M(0.0%) |
| Mar 1998 | - | $3.70 M(>+9900.0%) | $3.70 M(>+9900.0%) |
| Dec 1997 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 1997 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 1997 | - | $0.00(0.0%) | $10.00 M(-2.0%) |
| Mar 1997 | - | $0.00(0.0%) | $10.20 M(0.0%) |
| Dec 1996 | $10.20 M(+52.2%) | $0.00(-100.0%) | $10.20 M(-38.9%) |
| Sept 1996 | - | $10.00 M(+4900.0%) | $16.70 M(+142.0%) |
| June 1996 | - | $200.00 K(>+9900.0%) | $6.90 M(+3.0%) |
| Mar 1996 | - | $0.00(-100.0%) | $6.70 M(0.0%) |
| Dec 1995 | $6.70 M(>+9900.0%) | $6.50 M(+3150.0%) | $6.70 M(+3250.0%) |
| Sept 1995 | - | $200.00 K(>+9900.0%) | $200.00 K(>+9900.0%) |
| June 1995 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1995 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 1994 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 1994 | - | $0.00(0.0%) | $17.50 M(0.0%) |
| June 1994 | - | $0.00(0.0%) | $17.50 M(-0.6%) |
| Mar 1994 | - | $0.00(-100.0%) | $17.60 M(-0.6%) |
| Dec 1993 | $17.70 M(+5800.0%) | $17.50 M(>+9900.0%) | $17.70 M(+8750.0%) |
| Sept 1993 | - | $0.00(-100.0%) | $200.00 K(0.0%) |
| June 1993 | - | $100.00 K(0.0%) | $200.00 K(0.0%) |
| Mar 1993 | - | $100.00 K(>+9900.0%) | $200.00 K(-60.0%) |
| Dec 1992 | $300.00 K(-98.4%) | - | - |
| Oct 1992 | - | $0.00(-100.0%) | $500.00 K(0.0%) |
| July 1992 | - | $100.00 K(-80.0%) | $500.00 K(-97.3%) |
| Apr 1992 | - | $500.00 K(-600.0%) | $18.20 M(-1.6%) |
| Apr 1992 | $18.20 M(+2175.0%) | - | - |
| Jan 1992 | - | -$100.00 K(<-9900.0%) | $18.50 M(-0.5%) |
| Oct 1991 | - | $0.00(-100.0%) | $18.60 M(0.0%) |
| July 1991 | - | $17.80 M(+2125.0%) | $18.60 M(+2225.0%) |
| Apr 1991 | $800.00 K(-76.5%) | $800.00 K(>+9900.0%) | $800.00 K(>+9900.0%) |
| Jan 1991 | - | $0.00(0.0%) | $0.00(0.0%) |
| Oct 1990 | - | $0.00(0.0%) | $0.00(0.0%) |
| July 1990 | - | $0.00 | $0.00 |
| Apr 1990 | $3.40 M | - | - |
FAQ
- What is Celldex Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Celldex Therapeutics?
- What is Celldex Therapeutics annual CFF year-on-year change?
- What is Celldex Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly CFF year-on-year change?
- What is Celldex Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Celldex Therapeutics?
- What is Celldex Therapeutics TTM CFF year-on-year change?
What is Celldex Therapeutics annual cash flow from financing activities?
The current annual CFF of CLDX is $218.46 M
What is the all time high annual CFF for Celldex Therapeutics?
Celldex Therapeutics all-time high annual cash flow from financing activities is $289.60 M
What is Celldex Therapeutics annual CFF year-on-year change?
Over the past year, CLDX annual cash flow from financing activities has changed by +$214.38 M (+5259.62%)
What is Celldex Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of CLDX is $1.24 M
What is the all time high quarterly CFF for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly cash flow from financing activities is $436.11 M
What is Celldex Therapeutics quarterly CFF year-on-year change?
Over the past year, CLDX quarterly cash flow from financing activities has changed by +$982.00 K (+382.10%)
What is Celldex Therapeutics TTM cash flow from financing activities?
The current TTM CFF of CLDX is $658.44 M
What is the all time high TTM CFF for Celldex Therapeutics?
Celldex Therapeutics all-time high TTM cash flow from financing activities is $658.44 M
What is Celldex Therapeutics TTM CFF year-on-year change?
Over the past year, CLDX TTM cash flow from financing activities has changed by +$655.96 M (+26460.59%)